R emarkable events are unfolding at the Scripps Research Institute in La Jolla, California, where faculty members have rebelled against their president's attempts to merge with the University of Southern California (USC) in Los Angeles. These struggles are emblematic of today's difficult landscape for independent biomedical research institutes in the United States. Highly dependent on funding from the US National Institutes of Health (NIH), many independents have closed or merged with larger institutions (see Nature 491, 510; 2012), and Scripps president Michael Marletta wanted his centre to join that trend. In June, news leaked that Marletta had brokered a potential deal that would have seen USC pay Scripps US$600 million so that the two institutions could join up.
But in an interesting departure from the script, Scripps faculty members have said no to the deal, have argued against its entire basis and have now taken matters into their own hands. As we report on page 274, they have passed a vote of no confidence in Marletta by a startling margin -almost unanimously. They say that they can solve Scripps' financial crisis without his help, thank you very much, and can do so without selling out the institution that they love. Are they right? Other labs are watching with interest.
The impasse is a product of clashing views on Scripps, a prestigious independent institute that regularly attracts more than $300 million a year in NIH funding -upwards of 80% of the institute's operating budget. A sizeable chunk of the rest has tended to come from the pharmaceutical industry, but that has declined sharply in recent years, leaving the institute with a projected $21-million budget gap for this fiscal year.
But where Marletta sees this deficit as a problem necessitating a change in how Scripps does business, faculty members claim that it is a temporary setback, not an existential threat, and one that should be solved without changing the nature of their institute. They fear that a merger with USC would compromise their cherished independence -many point out that although they would get more job security at larger institutions, they have chosen to work at Scripps because its small size and non-hierarchical nature free them from administrative burdens and teaching that would distract them from science. And they are angry at Marletta's decision to negotiate the USC deal in secret, feeling that as Scripps' main breadwinners, they deserved to know much earlier that he was even considering such a move.
The closed-door negotiations have raised suspicions among faculty members that Marletta does not understand their priorities -or worse, that he does not share them. They think that the $600 million he agreed to, which was to be meted out in $15-million increments over 40 years, was a vast undervaluing of Scripps assets, including its formidable grant money, sizeable investments and coveted seaside location. To many, the deal felt like a land grab by USC, which would have paid a bargain rate for scientific prestige, a valuable piece of land T he global effort to eradicate poliomyelitis has been spectacularly successful, eliminating 99% of cases in its 26-year history. But that progress has begun to unravel in the past 18 months, with outbreaks in east and west Africa and in the Middle East. The lesson is clear: as long as the virus is allowed to persist in the three countries in which it remains endemic -Pakistan, Afghanistan and Nigeria -exports of the disease will continue to affect other countries. A determined effort is needed to eradicate the virus from these endemic countries, and fast.
The worsening situation meant that in May, the World Health Organization (WHO) declared polio a public-health emergency of 
